+Follow
gpp86
No personal profile
0
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
gpp86
2023-04-05
Sounds good
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?
gpp86
2023-04-05
Try 2 learn being a bussiness man
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4143742820634822","uuid":"4143742820634822","gmtCreate":1680639715849,"gmtModify":1680652343686,"name":"gpp86","pinyin":"gpp86","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9948824715,"gmtCreate":1680678130538,"gmtModify":1680679098813,"author":{"id":"4143742820634822","authorId":"4143742820634822","name":"gpp86","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4143742820634822","authorIdStr":"4143742820634822"},"themes":[],"htmlText":"Sounds good","listText":"Sounds good","text":"Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9948824715","repostId":"2324248860","repostType":4,"repost":{"id":"2324248860","pubTimestamp":1680679048,"share":"https://ttm.financial/m/news/2324248860?lang=&edition=fundamental","pubTime":"2023-04-05 15:17","market":"us","language":"en","title":"Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2324248860","media":"Motley Fool","summary":"These blue chips are down. Is it time to buy?","content":"<html><head></head><body><h2 style=\"text-align: start;\">KEY POINTS</h2><ul><li><p>Honeywell is coming off a strong fourth quarter, but sees moderating growth in 2023.</p></li><li><p>Johnson & Johnson is dealing with costly litigation over its baby powder.</p></li><li><p>3M is also facing lawsuits and expects earnings and sales to decline this year.</p></li></ul><p>The <strong>Dow Jones Industrial Average</strong> managed to post a small gain in the first quarter of 2023. Unfortunately, not all 30 stocks participated in the modest move higher. A few stocks actually dropped more than 10% in the first three months of the year. </p><p>Let's take a closer look at the three worst-performing stocks in the Dow Jones Industrials through the end of March (in reverse order of performance) to see if any of them are worth buying.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/545c3e8a9c4245d6cf3ab0d0db1784b7\" alt=\"Image source: Getty Images.\" title=\"Image source: Getty Images.\" tg-width=\"700\" tg-height=\"466\"/><span>Image source: Getty Images.</span></p><p></p><h2>3. Honeywell (down 11.8%)</h2><p><strong>Honeywell</strong>, like other industrial companies, has struggled on both sides of the income statement, facing weakening demand and rising costs due to inflation.</p><p>As a result, the stock has drifted lower over the course of the first quarter, missing out on the broader recovery in the stock market.</p><p>Other than its fourth-quarter earnings report, the main news out on the company so far this year is that current president and chief operating officer Vimal Kapur will succeed Darius Adamczyk on June 1.</p><p>Honeywell's top-line growth in the fourth quarter was solid with organic sales, which exclude currency exchange, up 10%, and reported revenue rose 6% to $9.19 billion, slightly below the consensus at $9.25 billion. </p><p>On the bottom line, Honeywell's adjusted earnings per share (EPS) improved, up from $2.09 to $2.52, but that was in line with analyst estimates.</p><p>Honeywell expects just modest growth in 2023 calling for 2% to 5% organic sales growth to $36 billion to $37 billion, and adjusted EPS growth of flat to 5%, reaching $8.80 to $9.20.</p><p>Based on that forecast, the stock trades at a price-to-earnings ratio of 21, and it could be vulnerable to a recession as it sells big-ticket times like smart building management systems and aircraft engines.</p><p>Given that, investors may be able to find better value elsewhere.</p><h2>2. Johnson & Johnson (down 13.1%)</h2><p>It's hard to find a safer stock than <strong>Johnson & Johnson</strong>. The company operates in healthcare, a mostly recession-proof industry, and it's diversified across three business segments: consumer goods (like Tylenol), medical devices, and pharmaceuticals, though it will spin off its consumer goods division.</p><p>The healthcare giant is also only one of two U.S. companies, along with <strong>Microsoft</strong>, to enjoy a AAA credit rating from S&P Global Ratings, and it's a Dividend King, having raised its quarterly payout every year for more than 50 years.</p><p>However, those qualities haven't protected J&J this year as the stock is down 13% through the first quarter, and like Honeywell, the stock steadily declined over most of the quarter. </p><p>The healthcare conglomerate received some bad news on the legal front as an appeals court rejected the company's attempt to move roughly 40,000 lawsuits over its talc-based baby powder causing cancer to a bankruptcy court. That will likely raise the end cost to J&J, which some analysts have estimated to come to $10 billion.</p><p>The company also discontinued its RSV adult vaccine, a disappointment for investors.</p><p>In its January earnings report, the company called for modest EPS growth in 2023 at 3% to 5%, indicating 2023 could be a challenging year for the stock.</p><h2>1. <a href=\"https://laohu8.com/S/MMM\">3M</a> (down 14.3%)</h2><p>Like Johnson & Johnson, <strong>3M </strong>has struggled this year in part because of legal troubles.</p><p>The company is embroiled in multiple liability lawsuits including over faulty earplugs and "forever chemicals," or PFAS, as the company recently said it would stop making PFAS. </p><p>In fact, the recent ruling in the Johnson & Johnson case has negative implications for 3M's own litigation around its earplugs.</p><p>3M's earnings report was also a disappointment as the company called for 2023 earnings per share of $8.50 to $9, below the $9.88 it reported in 2022, and short of the Wall Street consensus at $10.22. It also expects revenue to fall 2% to 6% this year.</p><p>The weakness was due in part to macroeconomic challenges as the company is cutting 2,500 jobs, exiting Russia, facing challenges in China, and dealing with the litigation mentioned above.</p><p>Given that reality, the stock seems better off avoided for now.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-05 15:17 GMT+8 <a href=https://www.fool.com/investing/2023/04/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSHoneywell is coming off a strong fourth quarter, but sees moderating growth in 2023.Johnson & Johnson is dealing with costly litigation over its baby powder.3M is also facing lawsuits and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/04/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC","BK4206":"工业集团企业","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4568":"美国抗疫概念","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","HON":"霍尼韦尔","LU0122379950.USD":"贝莱德世界健康科学A2","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4512":"苹果概念","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","MMM":"3M","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","JNJ":"强生","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/04/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2324248860","content_text":"KEY POINTSHoneywell is coming off a strong fourth quarter, but sees moderating growth in 2023.Johnson & Johnson is dealing with costly litigation over its baby powder.3M is also facing lawsuits and expects earnings and sales to decline this year.The Dow Jones Industrial Average managed to post a small gain in the first quarter of 2023. Unfortunately, not all 30 stocks participated in the modest move higher. A few stocks actually dropped more than 10% in the first three months of the year. Let's take a closer look at the three worst-performing stocks in the Dow Jones Industrials through the end of March (in reverse order of performance) to see if any of them are worth buying.Image source: Getty Images.3. Honeywell (down 11.8%)Honeywell, like other industrial companies, has struggled on both sides of the income statement, facing weakening demand and rising costs due to inflation.As a result, the stock has drifted lower over the course of the first quarter, missing out on the broader recovery in the stock market.Other than its fourth-quarter earnings report, the main news out on the company so far this year is that current president and chief operating officer Vimal Kapur will succeed Darius Adamczyk on June 1.Honeywell's top-line growth in the fourth quarter was solid with organic sales, which exclude currency exchange, up 10%, and reported revenue rose 6% to $9.19 billion, slightly below the consensus at $9.25 billion. On the bottom line, Honeywell's adjusted earnings per share (EPS) improved, up from $2.09 to $2.52, but that was in line with analyst estimates.Honeywell expects just modest growth in 2023 calling for 2% to 5% organic sales growth to $36 billion to $37 billion, and adjusted EPS growth of flat to 5%, reaching $8.80 to $9.20.Based on that forecast, the stock trades at a price-to-earnings ratio of 21, and it could be vulnerable to a recession as it sells big-ticket times like smart building management systems and aircraft engines.Given that, investors may be able to find better value elsewhere.2. Johnson & Johnson (down 13.1%)It's hard to find a safer stock than Johnson & Johnson. The company operates in healthcare, a mostly recession-proof industry, and it's diversified across three business segments: consumer goods (like Tylenol), medical devices, and pharmaceuticals, though it will spin off its consumer goods division.The healthcare giant is also only one of two U.S. companies, along with Microsoft, to enjoy a AAA credit rating from S&P Global Ratings, and it's a Dividend King, having raised its quarterly payout every year for more than 50 years.However, those qualities haven't protected J&J this year as the stock is down 13% through the first quarter, and like Honeywell, the stock steadily declined over most of the quarter. The healthcare conglomerate received some bad news on the legal front as an appeals court rejected the company's attempt to move roughly 40,000 lawsuits over its talc-based baby powder causing cancer to a bankruptcy court. That will likely raise the end cost to J&J, which some analysts have estimated to come to $10 billion.The company also discontinued its RSV adult vaccine, a disappointment for investors.In its January earnings report, the company called for modest EPS growth in 2023 at 3% to 5%, indicating 2023 could be a challenging year for the stock.1. 3M (down 14.3%)Like Johnson & Johnson, 3M has struggled this year in part because of legal troubles.The company is embroiled in multiple liability lawsuits including over faulty earplugs and \"forever chemicals,\" or PFAS, as the company recently said it would stop making PFAS. In fact, the recent ruling in the Johnson & Johnson case has negative implications for 3M's own litigation around its earplugs.3M's earnings report was also a disappointment as the company called for 2023 earnings per share of $8.50 to $9, below the $9.88 it reported in 2022, and short of the Wall Street consensus at $10.22. It also expects revenue to fall 2% to 6% this year.The weakness was due in part to macroeconomic challenges as the company is cutting 2,500 jobs, exiting Russia, facing challenges in China, and dealing with the litigation mentioned above.Given that reality, the stock seems better off avoided for now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9948165120,"gmtCreate":1680652621461,"gmtModify":1680655427589,"author":{"id":"4143742820634822","authorId":"4143742820634822","name":"gpp86","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4143742820634822","authorIdStr":"4143742820634822"},"themes":[],"htmlText":"Try 2 learn being a bussiness man","listText":"Try 2 learn being a bussiness man","text":"Try 2 learn being a bussiness man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9948165120","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9948824715,"gmtCreate":1680678130538,"gmtModify":1680679098813,"author":{"id":"4143742820634822","authorId":"4143742820634822","name":"gpp86","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4143742820634822","authorIdStr":"4143742820634822"},"themes":[],"htmlText":"Sounds good","listText":"Sounds good","text":"Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9948824715","repostId":"2324248860","repostType":4,"repost":{"id":"2324248860","pubTimestamp":1680679048,"share":"https://ttm.financial/m/news/2324248860?lang=&edition=fundamental","pubTime":"2023-04-05 15:17","market":"us","language":"en","title":"Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2324248860","media":"Motley Fool","summary":"These blue chips are down. Is it time to buy?","content":"<html><head></head><body><h2 style=\"text-align: start;\">KEY POINTS</h2><ul><li><p>Honeywell is coming off a strong fourth quarter, but sees moderating growth in 2023.</p></li><li><p>Johnson & Johnson is dealing with costly litigation over its baby powder.</p></li><li><p>3M is also facing lawsuits and expects earnings and sales to decline this year.</p></li></ul><p>The <strong>Dow Jones Industrial Average</strong> managed to post a small gain in the first quarter of 2023. Unfortunately, not all 30 stocks participated in the modest move higher. A few stocks actually dropped more than 10% in the first three months of the year. </p><p>Let's take a closer look at the three worst-performing stocks in the Dow Jones Industrials through the end of March (in reverse order of performance) to see if any of them are worth buying.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/545c3e8a9c4245d6cf3ab0d0db1784b7\" alt=\"Image source: Getty Images.\" title=\"Image source: Getty Images.\" tg-width=\"700\" tg-height=\"466\"/><span>Image source: Getty Images.</span></p><p></p><h2>3. Honeywell (down 11.8%)</h2><p><strong>Honeywell</strong>, like other industrial companies, has struggled on both sides of the income statement, facing weakening demand and rising costs due to inflation.</p><p>As a result, the stock has drifted lower over the course of the first quarter, missing out on the broader recovery in the stock market.</p><p>Other than its fourth-quarter earnings report, the main news out on the company so far this year is that current president and chief operating officer Vimal Kapur will succeed Darius Adamczyk on June 1.</p><p>Honeywell's top-line growth in the fourth quarter was solid with organic sales, which exclude currency exchange, up 10%, and reported revenue rose 6% to $9.19 billion, slightly below the consensus at $9.25 billion. </p><p>On the bottom line, Honeywell's adjusted earnings per share (EPS) improved, up from $2.09 to $2.52, but that was in line with analyst estimates.</p><p>Honeywell expects just modest growth in 2023 calling for 2% to 5% organic sales growth to $36 billion to $37 billion, and adjusted EPS growth of flat to 5%, reaching $8.80 to $9.20.</p><p>Based on that forecast, the stock trades at a price-to-earnings ratio of 21, and it could be vulnerable to a recession as it sells big-ticket times like smart building management systems and aircraft engines.</p><p>Given that, investors may be able to find better value elsewhere.</p><h2>2. Johnson & Johnson (down 13.1%)</h2><p>It's hard to find a safer stock than <strong>Johnson & Johnson</strong>. The company operates in healthcare, a mostly recession-proof industry, and it's diversified across three business segments: consumer goods (like Tylenol), medical devices, and pharmaceuticals, though it will spin off its consumer goods division.</p><p>The healthcare giant is also only one of two U.S. companies, along with <strong>Microsoft</strong>, to enjoy a AAA credit rating from S&P Global Ratings, and it's a Dividend King, having raised its quarterly payout every year for more than 50 years.</p><p>However, those qualities haven't protected J&J this year as the stock is down 13% through the first quarter, and like Honeywell, the stock steadily declined over most of the quarter. </p><p>The healthcare conglomerate received some bad news on the legal front as an appeals court rejected the company's attempt to move roughly 40,000 lawsuits over its talc-based baby powder causing cancer to a bankruptcy court. That will likely raise the end cost to J&J, which some analysts have estimated to come to $10 billion.</p><p>The company also discontinued its RSV adult vaccine, a disappointment for investors.</p><p>In its January earnings report, the company called for modest EPS growth in 2023 at 3% to 5%, indicating 2023 could be a challenging year for the stock.</p><h2>1. <a href=\"https://laohu8.com/S/MMM\">3M</a> (down 14.3%)</h2><p>Like Johnson & Johnson, <strong>3M </strong>has struggled this year in part because of legal troubles.</p><p>The company is embroiled in multiple liability lawsuits including over faulty earplugs and "forever chemicals," or PFAS, as the company recently said it would stop making PFAS. </p><p>In fact, the recent ruling in the Johnson & Johnson case has negative implications for 3M's own litigation around its earplugs.</p><p>3M's earnings report was also a disappointment as the company called for 2023 earnings per share of $8.50 to $9, below the $9.88 it reported in 2022, and short of the Wall Street consensus at $10.22. It also expects revenue to fall 2% to 6% this year.</p><p>The weakness was due in part to macroeconomic challenges as the company is cutting 2,500 jobs, exiting Russia, facing challenges in China, and dealing with the litigation mentioned above.</p><p>Given that reality, the stock seems better off avoided for now.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-05 15:17 GMT+8 <a href=https://www.fool.com/investing/2023/04/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSHoneywell is coming off a strong fourth quarter, but sees moderating growth in 2023.Johnson & Johnson is dealing with costly litigation over its baby powder.3M is also facing lawsuits and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/04/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC","BK4206":"工业集团企业","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4568":"美国抗疫概念","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","HON":"霍尼韦尔","LU0122379950.USD":"贝莱德世界健康科学A2","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4512":"苹果概念","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","MMM":"3M","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","JNJ":"强生","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/04/03/is-it-time-to-buy-the-dow-jones-3-worst-performing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2324248860","content_text":"KEY POINTSHoneywell is coming off a strong fourth quarter, but sees moderating growth in 2023.Johnson & Johnson is dealing with costly litigation over its baby powder.3M is also facing lawsuits and expects earnings and sales to decline this year.The Dow Jones Industrial Average managed to post a small gain in the first quarter of 2023. Unfortunately, not all 30 stocks participated in the modest move higher. A few stocks actually dropped more than 10% in the first three months of the year. Let's take a closer look at the three worst-performing stocks in the Dow Jones Industrials through the end of March (in reverse order of performance) to see if any of them are worth buying.Image source: Getty Images.3. Honeywell (down 11.8%)Honeywell, like other industrial companies, has struggled on both sides of the income statement, facing weakening demand and rising costs due to inflation.As a result, the stock has drifted lower over the course of the first quarter, missing out on the broader recovery in the stock market.Other than its fourth-quarter earnings report, the main news out on the company so far this year is that current president and chief operating officer Vimal Kapur will succeed Darius Adamczyk on June 1.Honeywell's top-line growth in the fourth quarter was solid with organic sales, which exclude currency exchange, up 10%, and reported revenue rose 6% to $9.19 billion, slightly below the consensus at $9.25 billion. On the bottom line, Honeywell's adjusted earnings per share (EPS) improved, up from $2.09 to $2.52, but that was in line with analyst estimates.Honeywell expects just modest growth in 2023 calling for 2% to 5% organic sales growth to $36 billion to $37 billion, and adjusted EPS growth of flat to 5%, reaching $8.80 to $9.20.Based on that forecast, the stock trades at a price-to-earnings ratio of 21, and it could be vulnerable to a recession as it sells big-ticket times like smart building management systems and aircraft engines.Given that, investors may be able to find better value elsewhere.2. Johnson & Johnson (down 13.1%)It's hard to find a safer stock than Johnson & Johnson. The company operates in healthcare, a mostly recession-proof industry, and it's diversified across three business segments: consumer goods (like Tylenol), medical devices, and pharmaceuticals, though it will spin off its consumer goods division.The healthcare giant is also only one of two U.S. companies, along with Microsoft, to enjoy a AAA credit rating from S&P Global Ratings, and it's a Dividend King, having raised its quarterly payout every year for more than 50 years.However, those qualities haven't protected J&J this year as the stock is down 13% through the first quarter, and like Honeywell, the stock steadily declined over most of the quarter. The healthcare conglomerate received some bad news on the legal front as an appeals court rejected the company's attempt to move roughly 40,000 lawsuits over its talc-based baby powder causing cancer to a bankruptcy court. That will likely raise the end cost to J&J, which some analysts have estimated to come to $10 billion.The company also discontinued its RSV adult vaccine, a disappointment for investors.In its January earnings report, the company called for modest EPS growth in 2023 at 3% to 5%, indicating 2023 could be a challenging year for the stock.1. 3M (down 14.3%)Like Johnson & Johnson, 3M has struggled this year in part because of legal troubles.The company is embroiled in multiple liability lawsuits including over faulty earplugs and \"forever chemicals,\" or PFAS, as the company recently said it would stop making PFAS. In fact, the recent ruling in the Johnson & Johnson case has negative implications for 3M's own litigation around its earplugs.3M's earnings report was also a disappointment as the company called for 2023 earnings per share of $8.50 to $9, below the $9.88 it reported in 2022, and short of the Wall Street consensus at $10.22. It also expects revenue to fall 2% to 6% this year.The weakness was due in part to macroeconomic challenges as the company is cutting 2,500 jobs, exiting Russia, facing challenges in China, and dealing with the litigation mentioned above.Given that reality, the stock seems better off avoided for now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9948165120,"gmtCreate":1680652621461,"gmtModify":1680655427589,"author":{"id":"4143742820634822","authorId":"4143742820634822","name":"gpp86","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4143742820634822","authorIdStr":"4143742820634822"},"themes":[],"htmlText":"Try 2 learn being a bussiness man","listText":"Try 2 learn being a bussiness man","text":"Try 2 learn being a bussiness man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9948165120","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
